m
Recent Posts
Connect with:
Tuesday / November 17.
HomemitechnologyTecnis PureSee: Why it’s Prof Gerard Sutton’s Go-To IOL

Tecnis PureSee: Why it’s Prof Gerard Sutton’s Go-To IOL

Johnson & Johnson’s Tecnis PureSee with Tecnis Simplicity Delivery System – a purely refractive presbyopia-correcting extended depth-of-focus (EDOF) intraocular lens (IOL) – has become a go-to lens for Professor Gerard Sutton’s refractive cataract patients.

mivision sat down with Prof Sutton to find out what initially impressed him about the lens, and why it continues to do so.

Q. What was it about Tecnis PureSee that gave you confidence to adopt this technology in your practice?

I’ve been a user of EDOF lenses for many years, and to me, they hit the sweet spot in terms of providing patients with a very good chance of minimising, if not eliminating, their need for glasses.

But the reason I moved to the PureSee was that I was convinced by the science that it would provide my patients with a more reliable chance of achieving social vision. And by that, I mean the ability to use their mobile phones, to check emails, to see the dashboard in the car, to go to the shops, to see what they were buying – but without compromising visual quality. And I think that the data do suggest the PureSee provides a quality of vision that is very similar to that provided by an aspheric monofocal lens.

Q. Which patients do you believe are best suited to Tecnis PureSee?

So the PureSee is the lens that I most commonly insert now. My practice has moved from rather complex corneal patients with eye disease to a more refractive practice. The patients that I think are best suited to PureSee are cataract patients who have no pathology, and all refractive surgery patients who are hyperopic and aged over 50.

Q. What feedback do you typically get about patients’ visual outcomes following Tecnis PureSee implantation?

I think the satisfaction rate [among my patients] is close to 100%.1 My strategy is always to target a plano correction in the dominant eye, and about -0.5 D in the non-dominant eye. In a recent audit of our patients at Vision Eye Institute, we found that 92% of patients could achieve 6/7.5 and read N8 without glasses, and I think that’s as good as, or better than, anything I’ve seen published.2

Q. Since introducing Tecnis PureSee, what clinical outcomes or real-world observations have been most influential in shaping your ongoing confidence in the lens?

I’m not averse to using multifocal or trifocal lenses, but I think that the disadvantage of those lenses in terms of visual quality and haloes – night-vision issues – means that it’s hard to justify using them, given that we’ve now got lenses that are as good as the PureSee.

I really haven’t had a complaint about night vision when driving with PureSee lenses. I’ve never, ever had to take out a PureSee lens for any visual quality issues. In fact, I’ve never taken out a PureSee that I put in for any reason.

Q. More than 100,000 Tecnis PureSee lenses have now been implanted across Australia and New Zealand.3 What does this milestone suggest about the evolution of cataract surgery and the changing expectations of both patients and surgeons?

Personally, I extend my congratulations to Johnson & Johnson; I think the fact that it has achieved the milestone of having 100,000 lenses implanted in Australia and New Zealand in such a short period of time means that the lens actually works; it’s not marketing. You can’t market that success.

I think that the results from the EDOF lenses, in particular, are such that if you are seeing a patient for cataract surgery, and you don’t at least discuss this option with them, then you are denying that patient the opportunity to make an important decision.

And the final thing I’d say is that if you’re going to be offering these lenses, it’s important to have a clear pathway for managing refractive outcomes after surgery. While many patients achieve excellent results, some may have a degree of residual refractive error that requires further attention. That pathway may involve managing the patient yourself, referring them to a refractive surgeon, performing a laser vision correction procedure, or implanting a secondary intraocular lens when appropriate.

Q. How have patient expectations changed over the past decade, and what role do you see newer lens technologies, such as Tecnis PureSee, playing in meeting those expectations?

Patients’ expectations today are higher than ever before, and that’s not unreasonable. Friends who’ve had cataract surgery tell them they are now independent of, or less dependent on, glasses, and so that’s what they expect when they walk into the ophthalmologist’s rooms. That’s the challenge that we have to accept – we can’t deny it or ignore it.

And I think they deserve to have the improved functionality that lenses like the PureSee offer – lenses that are able to not just improve spectacle-corrected vision, but to provide improved vision so they can function, to a large degree, without the need for spectacles.

That’s the reality in Australia today. And PureSee has been successful because Johnson & Johnson realised that reality and it’s meeting patients’ needs. This is what makes an ophthalmologist’s or an ophthalmic surgeon’s job that much easier, really.

This is a non-commissioned article. No payment was made to mivision or Professor Gerard Sutton for the preparation of this article. Prof Sutton is not a consultant for Johnson & Johnson.

Prof Gerard Sutton is one of Australia’s leading ophthalmic surgeons and is internationally recognised as an expert in laser vision correction and cataract surgery. A professor of ophthalmology at the University of Sydney, he established the world’s first university course in laser eye surgery. Prof Sutton practises with Vision Eye Institute in Sydney.

References

  1. Personal data on file (Vision Eye Institute).
  2. Data on file at Vision Eye Institute.
  3. mivision. Tecnis PureSee reaches 100,000 implants. 26 September 2026. Available at mivision.com.au/2026/09/tecnis-puresee-reaches-100000-implants [accessed Oct 2026].

This article is restricted to
Verified Health Practitioners only

Already registered?